Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Direct-acting antivirals for chronic hepatitis C: effects on fibrosis and patient-reported outcomes
NL-OMON42320Recruiting
- Sponsor
- Department of Gastroenterology and Hepatology
- Start
- Jan 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of sofosbuvir, simeprevir, daclatasvir, ledipasvir, paritaprevir and 3 more in hepatitis C virus infection, sponsored by Department of Gastroenterology and Hepatology. Primary endpoints: Liver stiffness measurements, Parameters of portal hypertension and 2 more. Started Jan 2015; status: recruiting.
02
Drugs
sofosbuvirsimeprevirdaclatasvirledipasvirparitaprevir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NL-OMON42320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42320.